Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: A canadian consensus statement

Kathleen I. Pritchard; K. A. Gelmon; D. Rayson; L. Provencher; M. Webster; D. McLeod; S. Verma

doi:10.3747/co.20.1316

Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: A canadian consensus statement

Kathleen I. Pritchard, K. A. Gelmon, D. Rayson, L. Provencher, M. Webster, D. McLeod, S. Verma

科研成果: 期刊稿件 › 文章 › 同行评审

源语言	英语
页（从-至）	48-61
页数	14
期刊	Current Oncology
卷	20
期	1
DOI	https://doi.org/10.3747/co.20.1316
出版状态	已出版 - 2013
已对外发布	是

!!!ASJC Scopus Subject Areas

肿瘤学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.3747/co.20.1316

其它文件与链接

指纹

探究 'Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: A canadian consensus statement' 的科研主题。它们共同构成独一无二的指纹。

引用此

Pritchard, K. I., Gelmon, K. A., Rayson, D., Provencher, L., Webster, M., McLeod, D., & Verma, S. (2013). Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: A canadian consensus statement. Current Oncology, 20(1), 48-61. https://doi.org/10.3747/co.20.1316

Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: A canadian consensus statement. / Pritchard, Kathleen I.; Gelmon, K. A.; Rayson, D. 等.
在: Current Oncology, 卷 20, 号码 1, 2013, 页码 48-61.

科研成果: 期刊稿件 › 文章 › 同行评审

Pritchard, KI, Gelmon, KA, Rayson, D, Provencher, L, Webster, M, McLeod, D & Verma, S 2013, 'Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: A canadian consensus statement', Current Oncology, 卷 20, 号码 1, 页码 48-61. https://doi.org/10.3747/co.20.1316

@article{8199868eb0644311b8100a612a4b8483,

title = "Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: A canadian consensus statement",

keywords = "Advanced breast cancer, Endocrine resistance, Endocrine therapy, Everolimus, Exemestane, Fulvestrant, Mtorinhibitor, Nonsteroidal aromatase inhibitor",

author = "Pritchard, {Kathleen I.} and Gelmon, {K. A.} and D. Rayson and L. Provencher and M. Webster and D. McLeod and S. Verma",

year = "2013",

doi = "10.3747/co.20.1316",

language = "English",

volume = "20",

pages = "48--61",

journal = "Current Oncology",

issn = "1198-0052",

publisher = "Multimed Inc.",

number = "1",

}

TY - JOUR

T1 - Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy

T2 - A canadian consensus statement

AU - Pritchard, Kathleen I.

AU - Gelmon, K. A.

AU - Rayson, D.

AU - Provencher, L.

AU - Webster, M.

AU - McLeod, D.

AU - Verma, S.

PY - 2013

Y1 - 2013

KW - Advanced breast cancer

KW - Endocrine resistance

KW - Endocrine therapy

KW - Everolimus

KW - Exemestane

KW - Fulvestrant

KW - Mtorinhibitor

KW - Nonsteroidal aromatase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84873444298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873444298&partnerID=8YFLogxK

U2 - 10.3747/co.20.1316

DO - 10.3747/co.20.1316

M3 - Article

AN - SCOPUS:84873444298

SN - 1198-0052

VL - 20

SP - 48

EP - 61

JO - Current Oncology

JF - Current Oncology

IS - 1

ER -